Prostate Cancer

William K. Oh, MD, discusses challenges with developing novel targeted agents in prostate cancer.

Clara Hwang, MD, discusses the phase 3 ERA-223 trial evaluating the addition of radium-223 dichloride to abiraterone acetate and prednisone in patients with metastatic castration-resistant prostate cancer and bone metastases.

Scott T. Tagawa, MD, MS, FACP, provides background on radionuclide therapy, sheds light on the key findings from the trial, and discusses future directions with 225Ac-J591 in mCRPC.

The combination of MRI-targeted and systemic biopsy led to increased detection of all prostate cancers in patients with MRI-visible lesions.

Alanna K. Rahm, PhD, MS, discusses alternate delivery models for genetic counseling in prostate cancer.

Julie N. Graff, MD, discusses potential combination regimens with checkpoint inhibitors in metastatic castration-resistant prostate cancer.

William K. Oh, MD, discusses adapting the phase 2 PRINT trial model to other settings in prostate cancer

Anis Hamid, MBBS, discusses potential combination with docetaxel in metastatic hormone-sensitive prostate cancer subtypes.

Charles L. Sawyers, MD, discusses the negative results on the IMbassador250 trial in metastatic castration-resistant prostate cancer.

Sam S. Chang, MD, MBA, discusses the importance of quality of life in prostate cancer.

Andrew J. Armstrong, MD, discusses the utility of PARP inhibitors in mutated prostate cancer.

Findings from the pivotal phase 3 PROfound trial of olaparib as a treatment for men with metastatic castration-resistant prostate cancer harboring homologous recombination repair (HRR) gene alterations were published in the New England Journal of Medicine.

Wolfgang Fendler, MD, discusses the utility and pending FDA approval of 68Ga-PSMA-11 PET in prostate cancer.

Richard (Rick) JaeBong Lee, MD, PhD, discusses choosing among the antidrogens available in the treatment of patients with nonmetastatic castration-resistant prostate cancer.

Himisha Beltran, MD, discusses the limitations of tissue biopsies versus liquid biopsies in castration-resistant neuroendocrine prostate cancer.

Neeraj Agarwal, MD, discusses the tolerability of apalutamide in metastatic castration-sensitive prostate cancer.

Eric Shinohara, MD, MSCI, discusses radiation therapy considerations for patients with prostate cancer.

Chris Parker, MD, discusses the optimal timing of salvage radiotherapy for men with prostate cancer.

Raoul S. Concepcion, MD, FACS, director, Comprehensive Prostate Center, discusses current testing patterns in urology practices.

James L. Mohler, MD, professor of oncology, associate director, and senior vice president of Translational Research, chief of Inter-Institutional Academics at Roswell Park Comprehensive Cancer Center, discusses recommendations for performing genetic testing in prostate cancer.

Rana R. McKay, MD, assistant professor of medicine and medical oncologist at the University of California, San Diego, discusses planned research in which investigators will evaluate the use of radium-223 dichloride (Xofigo) in patients with homologous recombination deficiency (HRD)-mutant metastatic castration-resistant prostate cancer (mCRPC).

Himisha Beltran, MD, discusses profiling of circulating tumor DNA to detect castration-resistant neuroendocrine prostate cancer.

Emmanuel S. Antonarakis, MBBCh, discusses the efficacy of radium-223 plus sipuleucel-T in patients with bone-metastatic castration-resistant prostate cancer and the next steps for research for this combination.

Olaparib improved overall survival in previously treated patients with metastatic castration-resistant prostate cancer harboring homologous recombination repair gene mutations.

Anis Hamid, MBBS, discusses next steps for precision medicine in metastatic hormone sensitive prostate cancer.